Company intelligence / Profile preview
Oxalo Therapeutics
Chicago, Illinois, United States
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Oxalo Therapeutics is developing a first-in-class microbiome-inspired oral peptide therapeutic that mimics Oxalobacter formigenes–driven intestinal oxalate transport to treat primary hyperoxaluria and prevent kidney stones; current public information indicates pre-clinical development and STTR-funded work on an oral peptide drug delivery system without reported human clinical trial results yet.[2][3]
- Therapeutic areas
- NephrologyRare Diseases
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Oxalo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxalo Therapeutics.